Suppr超能文献

厌食药:在全科医疗中的应用。

Anorectic drugs: use in general practice.

作者信息

Craddock D

出版信息

Drugs. 1976;11(5):378-93. doi: 10.2165/00003495-197611050-00002.

Abstract

The treatment of obesity is one of the major measures available today in the field of preventive medicine. In particular, the coronary epidemic of Western civilisation would be halted, and most cases of maturity-onset diabetes prevented, if obesity were to be treated effectively. Anorectic drugs act mainly on the satiety centre in the hypothalamus to produce anorexia. They also have various metabolic effects involving fat and carbohydrate metabolism, but many of these may be secondary to loss of weight. Most of the drugs are related directly or indirectly to amphetamine and in addition act by increasing general physical activity. Anorectic drugs tend to lose their effect after some months, and part of this reduction in effect may be due to chemical alterations produced by the drugs in the brain. All the drugs, with the exception of fenfluramine, have a stimulant effect on the central nervous system in some individuals, resulting in restlessness and nervousness, irritability and insomnia. Fenfluramine commonly produces drowsiness in normal doses, but has stimulant effects with overdosage. Dexamphetamine, phenmetrazine and benzphetamine all tend to cause euphoria and the risk of addiction is therefore considerable. Euphoria occasionally occurs with diethylpropion, phentermine and chlorphentermine, but to a much lesser extent. Side-effects also occur due to sympathetic stimulation and gastro-intestinal irritation. These side-effects may cause some individuals to stop taking the drug, but are never serious or dangerous. Drug interactions may occur with monoamine oxidase inhibitors and to a clinically unimportant extent, with antihypertensive drugs. The anorectic drugs have a very definite part to play in the treatment of obesity, mainly for those individuals who have altered their eating habits but have come to a plateau of weight which they find difficult to get below. The drugs are best given in a long-acting form and can safely be continued as long as weight loss persists, provided that the clinician exercises careful supervision. Dexamphetamine, phenmetrazine and benzphetamine should rarely be used because of the danger of addiction, and chlorphentermine is potentially hazardous for long-term use. Diethylpropion emerges as the drug of first choice, as fenfluramine has a tendency to cause depression and has a higher incidence of side-effects. Fenfluramine is mainly useful for people who are especially tense and for obese maturity-onset diabetics who have been unable to lose weight with the biguanides. Mazindol and phentermine appear to be useful as alternative drugs.

摘要

肥胖症的治疗是当今预防医学领域可用的主要措施之一。特别是,如果肥胖症能得到有效治疗,西方文明中的冠心病流行将会得到遏制,大多数成年型糖尿病病例也能得到预防。食欲抑制剂主要作用于下丘脑的饱食中枢以产生厌食效果。它们还对脂肪和碳水化合物代谢有各种代谢作用,但其中许多可能是体重减轻的继发效应。大多数这类药物直接或间接与苯丙胺有关,并且还通过增加总体身体活动起作用。食欲抑制剂在几个月后往往会失去效果,这种效果降低的部分原因可能是药物在大脑中产生的化学变化。除芬氟拉明外,所有这些药物在某些个体中对中枢神经系统有刺激作用,导致烦躁不安、紧张、易怒和失眠。芬氟拉明在正常剂量下通常会产生嗜睡,但过量服用时有刺激作用。右旋苯丙胺、苯甲曲秦和苄非他明都容易导致欣快感,因此成瘾风险相当大。二乙丙胺苯丙酮、苯丁胺和氯苯丁胺偶尔也会出现欣快感,但程度要小得多。还会因交感神经刺激和胃肠道刺激而出现副作用。这些副作用可能会使一些人停止服药,但从不严重或危险。与单胺氧化酶抑制剂可能会发生药物相互作用,与抗高血压药物的相互作用在临床上不重要。食欲抑制剂在肥胖症治疗中具有非常明确的作用,主要适用于那些改变了饮食习惯但体重达到一个难以再降低的平台期的个体。这些药物最好以长效形式给药,只要体重持续减轻,在临床医生仔细监督的情况下可以安全地持续使用。由于有成瘾危险,应很少使用右旋苯丙胺、苯甲曲秦和苄非他明,氯苯丁胺长期使用有潜在危险。二乙丙胺苯丙酮成为首选药物,因为芬氟拉明有导致抑郁的倾向且副作用发生率较高。芬氟拉明主要对特别紧张的人和使用双胍类药物无法减肥的肥胖成年型糖尿病患者有用。马吲哚和苯丁胺似乎可作为替代药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验